A recent investor presentation from Collagenex gives some hints as to how Collagenex will price COL-118. Collagenex believe that their anti erythema product used for 2-4 months of treatment at $150 a month leads to a $330-660 million market. $150 a month for COL-118 treatment sounds like a lot. One wonders how much the suggested $150 a month will translate to at the pharmacy counter.
PubMed pushed out an interesting abstract in the last couple of days. A bit of digging reveals what looks to be a running mate for COL-118/Sansrosa. COL-118 and Oxymetazoline appear to be promoted by separate groups of researchers. This is good news for rosacea sufferers as it means there may well be a choice between 2 topicals that can help address the redness and flushing of rosacea.
Alluding to a link between rosacea and migraines, Dr. Joseph Bikowski says that aspirin should be the first line of defense against rosacea flushing. A recent article in Dermatology Times highlights the potential benefits (and risks) of taking low doses of aspirin long term for rosacea swelling and flushing.
Getting some press in Australia currently is a story about a trial starting today in Melbourne. The trial will assess the efficacy of CUV1647 (also known as melanotan) to protect against skin cancer in patients who have had organ transplants. Patients who have received organ transplants are at a much higher risk of contracting skin cancer because of the immune suppressive drugs that they must take.